Cardiovascular disease is the leading cause of death. Standard cholesterol tests can miss that YOU are at risk. SpectraCell’s CardioMetabolic test offers a clinically relevant evaluation to help define risk for atherosclerotic cardiovascular disease (ASCVD), progression toward Type 2 Diabetes, and inflammation. It includes SpectraCell’s Advanced Lipoprotein Particle Profile™ Plus (LPPTM Plus), which measures lipoprotein size and density; cardiovascular risk stratification; and also includes triglycerides and traditional cholesterol screening. Each patient is assigned a CardioMetabolic Risk Assessment, which is an indication of your risk (Low, Moderate or High) for developing cardiovascular disease, including stroke and diabetes. In addition, the Type 2 Diabetes Risk Assessment is an estimate of your risk of developing Type 2 Diabetes. These check points help patients understand that not just one factor, but rather a constellation of risk factors, contribute to the genesis and progression toward poor blood sugar control and/or ASCVD. Results of testing allow doctors to know when guidance, educational referral, or treatment is necessary.
All patients, and especially those who: